M&A

Subsidiary of Molex, Phillips Medisize, has announced the successful acquisition of Vectura Group Ltd. The acquisition was completed through an affiliate.

Vectura Fertin Pharma, specialises in the development of drug delivery platforms, including nasal delivery, nebulisers, powders and metered-dose inhalers. This expertise will be transferred over to Molex, including two branded platforms and one trademarked device. Pharmaceutical R&D company Phillips Medisize will now be able to build on the services it can offer to clients in the inhalation drug delivery.

“Phillips Medisize will continue to expand the services we offer pharmaceutical companies thanks to the acquisition of Vectura, particularly in inhalation, to help meet growing patient needs.

Together Phillips Medisize and Vectura are uniquely positioned to collaborate with leading pharmaceutical customers to develop innovative products that address the growing global demand for new therapies to treat chronic respiratory diseases like asthma and COPD, as well as non-respiratory conditions,” said Paul Chaffin, president of Phillips Medisize.

In addition to inhalation expertise, Phillips Medisize will increase its staff size by approximately 350 members to its current list of over 6,000. Experts include scientists and engineers, creating a more united front in Phillip Medisize’s mission to enable global development, design, manufacturing and formulation over its 30 sites spread across three continents.